Cargando...
Use of selexipag in a teenage patient with pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a chronic, progressive, multifactorial disease. Currently, combination therapy is an attractive option for PAH management because three pathways (endothelin, nitric oxide, and prostacyclin) are involved in this disease. Selexipag is a novel oral prostacyclin...
Gardado en:
| Publicado en: | Ann Pediatr Cardiol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Wolters Kluwer - Medknow
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7918021/ https://ncbi.nlm.nih.gov/pubmed/33679065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/apc.APC_63_19 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|